Contineum Therapeutics (CTNM) Operating Expenses (2023 - 2026)

Contineum Therapeutics' Operating Expenses history runs 4 years deep, the most recent figure standing at $17.4 million for Q2 2026.

• In Q2 2026, Operating Expenses fell 2.65% year-over-year to $17.4 million; the TTM figure through Jun 2026 stood at $66.4 million (up 0.52% YoY), while the FY2025 annual figure was $68.1 million, up 33.73% from the prior year.
• Operating Expenses for Q2 2026 stood at $17.4 million, up from $16.9 million in the prior quarter.
• The five-year high for Operating Expenses was $18.1 million in Q1 2025, with the low at $5.1 million in Q1 2023.
• The 4-year median for Operating Expenses is $14.0 million (2024), against an average of $13.4 million.
• The sharpest annual moves came in 2024 and 2026: Operating Expenses jumped 94.13% in 2024, then declined 6.66% in 2026.
• Contineum Therapeutics' Operating Expenses stood at $9.7 million in 2023, then soared by 76.18% to $17.0 million in 2024, then advanced by 0.4% to $17.1 million in 2025, then increased by 1.83% to $17.4 million in 2026.
• Business Quant data shows CTNM's Operating Expenses at $17.4 million in Q2 2026, $16.9 million in Q1 2026, and $17.1 million in Q4 2025.